Full Papers
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options
M. Fredi1, F. Bartoli2, I. Cavazzana3, A. Ceribelli4, N. Carabellese5, A. Tincani6, M. Satoh7, F. Franceschini8
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili, Brescia, Italy.
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili, Brescia; and Università degli Studi di Brescia, Italy.
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili Brescia, Italy. ilariacava@virgilio.it
- Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (Milan); and BIOMETRA Department, University of Milan, Italy.
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili, Brescia, Italy.
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili, Brescia; and Università degli Studi di Brescia, Italy.
- Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Fukuoka, Japan.
- Rheumatology and Clinical Immunology Unit, Rheumatology Chair, Spedali Civili, Brescia, Italy.
CER9657
2017 Vol.35, N°2
PI 0303, PF 0308
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 27908312 [PubMed]
Received: 13/06/2016
Accepted : 07/09/2016
In Press: 14/11/2016
Published: 15/03/2017
Abstract
OBJECTIVES:
We aimed to identify the possible clinical and laboratory predictors of calcinosis in a cohort of patients with a diagnosis of polymyositis (PM) and dermatomyositis (DM).
METHODS:
We carried out a retrospective analysis of a cohort of myositis patients attending our clinic between January 2013 and May 2014.
RESULTS:
74 patients (58 females, 16 males) with PM (30 cases), DM (30 cases), overlap syndrome (13 cases) and inclusion body myositis (1 case) were enrolled. Sixteen patients (21.6%) had calcinosis that occurred a mean of 43.7 months after diagnosis of PDM. At multivariate analysis, patients with calcinosis experienced longer follow-up duration (p=0.006), anti-PM/Scl (p=0.033) and anti-NXP2 (p=0.024) positivity compared to patients without calcinosis. Furthermore, anti-NXP-2 positive C+ showed a diffuse form of calcinosis from the beginning and lower frequency of respiratory tract involvement. No single drug or associations of drugs was found effective in the treatment of calcinosis.
CONCLUSIONS:
A longer follow-up period of time, DM diagnosis and positivity for PM/Scl and NXP-2 could all be considered risk factors which foresee the development of calcinosis. Moreover, the positivity for antibodies to NXP-2 depicts a distinct phenotype of calcinosis with an early onset and quick widespread dissemination.